Breaking Finance News

Insmed Incorporated (NASDAQ:INSM) has been upgraded to Hold in a report by Zacks Investment Research today.

Zacks Investment Research has upgraded Insmed Incorporated (NASDAQ:INSM) to Hold in a report released on 9/21/2016.

Yesterday Insmed Incorporated (NASDAQ:INSM) traded -1.60% lower at $14.73. The company’s 50-day moving average is $13.22 and its 200-day moving average is $12.00. With the last stock price close up 23.01% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Volume of trade was down over the average, with 277,260 shares of INSM changing hands under the typical 338,064

Performance Chart

Insmed Incorporated (NASDAQ:INSM)

With a total market value of $0, Insmed Incorporated has with a one year low of $9.02 and a one year high of $21.14 .

A total of 8 equity analysts have released a research note on INSM. One equity analyst rating the company a strong buy, four equity analysts rating the company a buy, two equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $23.63.

Brief Synopsis About Insmed Incorporated (NASDAQ:INSM)

Insmed Incorporated is a biopharmaceutical company. The Company operates in the segment of development and commercialization of inhaled therapies for patients with serious lung diseases. The Company's lead product candidate, ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for patients with nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. The Company's earlier stage pipeline includes INS1009, a nebulized prodrug formulation of treprostinil, a vasodilator of pulmonary arterial vascular beds. The Company is conducting a global Phase III clinical study of ARIKAYCE (the 212 or CONVERT study) in adult patients with NTM lung disease caused by Mycobacterium avium complex (MAC), the infective species in NTM lung disease in the United States, Europe and Japan.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *